SARS-CoV-2 Variants of Concern Delta: a great challenge to prevention and control of COVID-19

Li, Maochen; Lou, Fuxing; Fan, Huahao

doi:10.1038/s41392-021-00767-1

Cited by 59 publications

(55 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CoronaVac and HB02 are both authorized by the World Health Organization for emergency use and together accounted for almost half of the COVID-19 vaccine doses dispensed globally as of October 2021 ( 37 , 38 ). Therefore, our study has important policy implications.…”

Section: Discussionmentioning

confidence: 99%

Effectiveness of Inactivated COVID-19 Vaccines Against Illness Caused by the B.1.617.2 (Delta) Variant During an Outbreak in Guangdong, China

Kang

et al. 2022

Ann Intern Med

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Effectiveness of Inactivated COVID-19 Vaccines Against Illness Caused by the B.1.617.2 (Delta) Variant During an Outbreak in Guangdong, China

Kang

et al. 2022

Ann Intern Med

View full text Add to dashboard Cite

show abstract

“…The Delta variant of SARS-CoV-2 initially detected in India in September 2020 and had spread subsequently to 115 countries globally [4]. The emergence of the Delta variant in India was followed by a significant increase in the cases and in the positivity rate to reach 30% at the end of April 2021 [5].…”

Section: Introductionmentioning

confidence: 99%

COVID-19 Delta Variant: Perceptions, Worries, and Vaccine-Booster Acceptability among Healthcare Workers

et al. 2021

View full text Add to dashboard Cite

Background: As the COVID-19 Delta variant has spread across the globe, healthcare workers’ (HCWs) knowledge, worries, and vaccine booster acceptance should be assessed. Methods: Online questionnaires aimed at HCWs in Saudi Arabia were distributed between 9 and 12 August 2021, aiming to evaluate HCWs’ perceptions and worries about the Delta variant as well as their feelings about receiving a booster-vaccine. Results: A total of 1279 HCWs participated, with 51.1% being physicians and 41.7% nurses. 92.5% were aware of the emergence of the Delta variant. Still, only 28.7% were found to have sufficient knowledge of the variant, and their level of worry about it was higher than their level of worry about the Alpha variant (2.32/5 versus 1.79/5). The main information sources cited by the participants were social media (50.5%), while 30.5% used scientific journals. Overall, 55.3% were willing to receive a vaccine booster, while one third would have preferred to receive a new mRNA vaccine specifically developed for the Delta variant. Factors associated with vaccine booster acceptance were receiving both vaccination doses (p = 0.008), believing that the Pfizer-BioNTech BNT162b2 vaccine is effective against variants (p < 0.001), and agreement that mixing/matching vaccines is effective against variants (p < 0.001). Conclusions: A high percentage of HCWs were aware of the Delta variant, but only a small fraction had decent quality of knowledge about it. The participants exhibited high worry levels and showed a modest acceptance of receiving a vaccine booster dose. These results should encourage public health officials to scale up educational efforts to disseminate reliable information about the different variants and provide recommendations about receiving a vaccine booster. Further research on methods to alleviate HCWs’ worries about emerging variants is warranted.

show abstract

“…*) variant of SARS-CoV-2 that was first detected in India in late 2020 [ 6 ] is, as of November 2021, the prevalent lineage in most countries including Russia [ 7 ]. It was shown to be more infectious but also to cause higher mortality than earlier variants of concern [ 8 , 9 ]. The fast spread of Delta may be associated with its reduced sensitivity to neutralization by antibodies [ 10 ] as well as increased efficiency of fusion with human cells [ 11 ].…”

Section: Introductionmentioning

confidence: 99%

The rise and spread of the SARS-CoV-2 AY.122 lineage in Russia

Klink

Safina

Nabieva

et al. 2021

Preprint

View full text Add to dashboard Cite

BackgroundDelta has outcompeted most preexisting variants of SARS-CoV-2, becoming the globally predominant lineage by mid-2021. Its subsequent evolution has led to emergence of multiple sublineages, many of which are well-mixed between countries.AimHere, we aim to study the emergence and spread of the Delta lineage in Russia.MethodsWe use a phylogeographic approach to infer imports of Delta sublineages into Russia, and phylodynamic models to assess the rate of their spread.ResultsWe show that nearly the entire Delta epidemic in Russia has probably descended from a single import event despite genetic evidence of multiple Delta imports. Indeed, over 90% of Delta samples in Russia are characterized by the nsp2:K81N+ORF7a:P45L pair of mutations which is rare outside Russia, putting them in the AY.122 sublineage. The AY.122 lineage was frequent in Russia among Delta samples from the start, and has not increased in frequency in other countries where it has been observed, suggesting that its high prevalence in Russia has probably resulted from a random founder effect.ConclusionThe apartness of the genetic composition of the Delta epidemic in Russia makes Russia somewhat unusual, although not exceptional, among other countries.

show abstract

SARS-CoV-2 Variants of Concern Delta: a great challenge to prevention and control of COVID-19

Cited by 59 publications

References 5 publications

Effectiveness of Inactivated COVID-19 Vaccines Against Illness Caused by the B.1.617.2 (Delta) Variant During an Outbreak in Guangdong, China

Effectiveness of Inactivated COVID-19 Vaccines Against Illness Caused by the B.1.617.2 (Delta) Variant During an Outbreak in Guangdong, China

COVID-19 Delta Variant: Perceptions, Worries, and Vaccine-Booster Acceptability among Healthcare Workers

The rise and spread of the SARS-CoV-2 AY.122 lineage in Russia

Contact Info

Product

Resources

About